NEW YORK (CNN/Money) -
Pfizer Thursday reiterated its earnings and revenue projections for 2002, 2003 and 2004.
For 2002, Pfizer said it is comfortable with diluted earnings per share in the range of $1.56 to $1.60, excluding certain significant items and merger-related costs. Pfizer also expects double-digit revenue growth at current foreign exchange rates, continuing strong investments in product support and research and development as well as margin improvements in the year.
The consensus estimate of analysts surveyed by earnings tracker First Call sees Pfizer earning $1.59 a share in 2002.
For 2003 and 2004, Pfizer (PFE: Research, Estimates) has targets of double-digit revenue growth, strong investment, further margin improvements and average annual earnings per share growth of 15 percent or better, excluding certain significant items and merger-related costs. First Call's 2003 estimate calls for 2003 earnings per share of $1.84 and $2.14 in 2004.
The projections were first disclosed in the drug maker's January 23, 2002 quarterly earnings news release.
| || ||
|| || |
Pfizer Inc., which is headquartered in New York, researches, develops, manufactures and markets leading prescription medicines for humans and animals as well as consumer products such as Listerine mouthwash and Dentyne gum.